MarketCap
Facebook
X
Telegram
Adicet Bio Income Statement 2025-2011 | ACET
Brief overview of financial performance at Adicet Bio
The overview follows changes across a five-year period. Revenue at Adicet Bio moved from 559 million dollars in 2017 to 25 million dollars in 2022. The total change was −95.5%, with a CAGR of approximately −46.3%. Revenue ended the period on a sustained downward trend.
The five-year EBITDA result moved by −194.3%: from $74.2 million to −$70 million. EBITDA underperformed the top-line trend. EBITDA margin was 13.3% at the start and −280% at the end. A lower EBITDA share weakens the quality of the result.
Across the five years, the net result shifted from 34.8 million dollars to −69.8 million dollars. Profit turned into a loss, the most concerning signal in the results.
Summary assessment
The financial trajectory is weak and requires a cautious interpretation. The overall view is constrained by a weaker final result, limited operating profitability and a softer top-line trend. Further direction will depend on top-line growth, operating profitability, and net income.
Annual Income Statement Adicet Bio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
48.5 M | 4.61 M | 87.4 M | 317 M | 541 M | 64.1 M | 289 M | - | - | - | - | - | - | - | - |
Shares |
6.89 M | 5.49 M | 43 M | 41.1 M | 31 M | 5.21 M | 32.3 M | - | - | - | - | - | - | - | - |
Historical Prices |
7.04 | 0.84 | 2.03 | 7.72 | 17.5 | 14.1 | 10.4 | 60.3 | - | - | - | - | - | - | - |
Net Income |
-117 M | -117 M | -143 M | -69.8 M | -62 M | -36.7 M | -28.1 M | 11.4 M | 34.8 M | 33.5 M | 29 M | 22.3 M | 22.3 M | 17 M | 8.97 M |
Revenue |
- | - | - | 25 M | 9.73 M | 17.9 M | 995 K | 638 M | 559 M | 547 M | 510 M | 500 M | 500 M | 444 M | 412 M |
Gross Profit |
- | - | - | - | - | 17.9 | - | 141 M | 143 M | 135 M | 115 M | 98.3 M | 98.3 M | 82 M | 65.8 M |
Operating Income |
-122 M | -128 M | -152 M | -72.6 M | -61.4 M | -39.2 M | -31.4 M | -15 M | -18.9 M | - | - | - | - | - | - |
Interest Expense |
36 K | 4 K | 25 K | 80 K | 176 K | 134 K | 2.33 M | 4.53 M | -14.9 M | - | - | - | - | - | - |
EBITDA |
-116 M | -121 M | -146 M | -70 M | -59.9 M | -38 M | -30.2 M | 65.2 M | 74.2 M | 68.2 M | 52.4 M | 41.4 M | 41.4 M | 32.3 M | 22.1 M |
Operating Expenses |
122 M | 128 M | 152 M | 97.5 M | 71.2 M | 57.1 M | - | 110 M | 84.8 M | 79.1 M | 70.4 M | 63.9 M | 63.9 M | 56.7 M | 49.3 M |
General and Administrative Expenses |
23 M | 28.3 M | 26.5 M | 26.3 M | 22.2 M | 22.8 M | 8.69 M | 102 M | 76.8 M | 73.2 M | 65.2 M | 61 M | 63.9 M | 56.7 M | 49.3 M |
All numbers in USD currency
Quarterly Income Statement Adicet Bio
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
10.7 M | 91.1 M | 91.1 M | 91.1 M | 82.6 M | 90.8 M | 90.6 M | 79.1 M | 43.3 M | 43 M | 43 M | 43 M | 43 M | 41.6 M | 40.1 M | 39.8 M | 39.7 M | 31.9 M | 31.8 M | 26.1 M | 39.7 M | 5.21 M | 2.18 M | 2.16 M | 2.16 M | 2.15 M | 35.7 M | 29 M | 28.1 M | 28 M | 28 M | 21.5 M | 5.66 M | 4.41 M | 4.3 M | 2.79 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-20.2 M | -26.9 M | -31.2 M | -28.2 M | - | -30.5 M | -29.9 M | -28 M | - | -49.9 M | -32.4 M | -30.9 M | - | -22 M | -22.5 M | 4.62 M | - | -14 M | -10.9 M | -21.3 M | - | -14.8 M | -8.46 M | -4.49 M | -28.9 M | -14.8 M | -2.65 M | -4.13 M | -5.76 M | -8.41 M | -13.6 M | -9.86 M | -23.1 M | -3.31 M | -4.06 M | -3.36 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 25 M | - | 3.43 M | 4.81 M | -3.98 M | - | 3.03 M | 7.46 M | 2 M | - | -7.05 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-21.6 M | -28 M | -32.4 M | -29.9 M | - | -33.2 M | -32.8 M | -30.9 M | - | -52.3 M | -34.9 M | -33.3 M | - | -23 M | -22.7 M | 4.71 M | - | -13.7 M | -10.8 M | -21.4 M | - | -13.7 M | -8.63 M | -7.56 M | -29.4 M | -15.2 M | -19.2 M | -11.7 M | -6.36 M | -9.03 M | -14.1 M | -10.2 M | -7.52 M | -3.94 M | -4.06 M | -3.36 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
23 K | 12 K | - | - | - | 1 K | - | 2 K | - | 1 K | 4 K | 19 K | - | 18 K | 18 K | 18 K | - | 50 K | 51 K | 50 K | - | 50 K | 34 K | 70 K | - | 171 K | 847 K | 631 K | - | 625 K | 522 K | 341 K | - | 635 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-20.2 M | -26.4 M | -30.8 M | -28.2 M | - | -31.6 M | -31.2 M | -29.2 M | - | -50.7 M | -33.4 M | -32.1 M | - | -22.2 M | -22.3 M | 5.06 M | - | -13.3 M | -10.3 M | -21 M | - | -13.4 M | -8.33 M | -7.24 M | -29.4 M | -14.9 M | -19.1 M | -11.7 M | -6.36 M | -9.01 M | -14.1 M | -10.2 M | -7.52 M | -3.94 M | -4.06 M | -3.36 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
21.6 M | 28 M | 32.4 M | 29.9 M | - | 33.2 M | 32.8 M | 30.9 M | - | 52.3 M | 34.9 M | 33.3 M | - | 23 M | 22.7 M | 20.3 M | - | 17.1 M | 15.6 M | 17.4 M | - | 16.7 M | 16.1 M | 9.56 M | - | 8.18 M | 19.2 M | 11.7 M | - | 9.03 M | 14.1 M | 10.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
4.08 M | 5.1 M | 3.97 M | 7.07 M | - | 6.9 M | 6.95 M | 6.97 M | - | 6.63 M | 6.53 M | 6.57 M | - | 6.42 M | 6.53 M | 6.8 M | - | 5.21 M | 5.02 M | 5.63 M | - | 7.74 M | 7.42 M | 2.52 M | - | 1.85 M | 2.62 M | 2.84 M | - | 2.27 M | 2.27 M | 2.09 M | - | 612 K | 637 K | 63 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Adicet Bio (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Chemicals industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Molecular Data
MKD
|
- | 2.5 % | $ 2.3 M |  China |
 |
Роллман
RLMN
|
- | - | - |  Russia |
 |
Куйбышевазот
KAZT
|
- | - | - | Russia |
 |
Казаньоргсинтез
KZOS
|
- | - | - | Russia |
 |
Ciner Resources LP
CINR
|
- | 0.81 % | $ 344 M |  USA |
 |
Tronox Holdings plc
TROX
|
$ 6.24 | -2.27 % | $ 989 M | USA |
 |
Methanex Corporation
MEOH
|
$ 55.86 | -3.67 % | $ 4.05 B |  Canada |
 |
Celanese Corporation
CE
|
$ 46.43 | -1.94 % | $ 5.09 B | USA |
 |
Univar Solutions
UNVR
|
- | -0.01 % | $ 5.99 B | USA |
 |
Ashland Global Holdings
ASH
|
$ 66.4 | -0.24 % | $ 3.05 B | USA |
 |
AdvanSix
ASIX
|
$ 21.05 | -1.75 % | $ 566 M | USA |
 |
Braskem S.A.
BAK
|
$ 2.46 | -0.4 % | $ 4.36 B |  Brasil |
 |
FutureFuel Corp.
FF
|
$ 4.65 | -1.48 % | $ 204 M | USA |
 |
Dow
DOW
|
$ 29.84 | -3.4 % | $ 21.2 B | USA |
 |
Sociedad Química y Minera de Chile S.A.
SQM
|
$ 68.73 | -0.92 % | $ 19.6 B |  Chile |
 |
DuPont de Nemours
DD
|
$ 137.7 | 0.23 % | $ 57.5 B | USA |
 |
LSB Industries
LXU
|
$ 12.24 | 0.25 % | $ 881 M | USA |
 |
Rayonier Advanced Materials
RYAM
|
$ 8.38 | -0.71 % | $ 560 M | USA |
 |
Eastman Chemical Company
EMN
|
$ 68.2 | 0.41 % | $ 7.82 B | USA |
 |
Huntsman Corporation
HUN
|
$ 12.8 | -0.04 % | $ 2.21 B | USA |
 |
Minerals Technologies
MTX
|
$ 74.6 | 1.9 % | $ 2.34 B | USA |
 |
Valhi
VHI
|
$ 13.62 | 0.37 % | $ 388 | USA |
 |
Westlake Chemical Partners LP
WLKP
|
$ 22.05 | 0.18 % | $ 777 M | USA |
 |
Air Products and Chemicals
APD
|
$ 297.87 | 1.22 % | $ 66.3 B | USA |